Using Plasma from Recovered Covid-19 Patients Shows Little Benefit in Severe Cases

An Argentine study involved 333 hospitalized patients with severe COVID-19 pneumonia who were randomly assigned to receive convalescent plasma or a placebo.

RIO DE JANEIRO, BRAZIL - Using blood plasma from COVID-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released on Tuesday, November 24th, from a clinical trial in Argentina.

The therapy know as convalescent plasma, which delivers antibodies from COVID-19 survivors to infected people, did not significantly improve patients’ health status or reduce their risk of dying from the disease any better than a placebo, the study published in The New England Journal of Medicine found.

Despite limited evidence of its efficacy, convalescent plasma, which U.S. President Donald . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?